Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan

Vascular Health and Risk Management

Volumn 10, Issue , 2014, Pages 15-24

  Schweizer, Anja ^a   Halimi, Serge ^b,c   Dejager, Sylvie ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c UNIV GRENOBLE ALPES   (France)

^d NOVARTIS PHARMA K K   (Japan)

Author keywords

Dipeptidyl peptidase 4; Hypoglycemia; Incretin; Type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; METFORMIN PLUS SITAGLIPTIN; PLACEBO; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ACUTE PANCREATITIS; ADD ON THERAPY; ADVERSE OUTCOME; BRAIN ISCHEMIA; DIET RESTRICTION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; MALAISE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; WEIGHT CHANGE;

DIPEPTIDYL PEPTIDASE-4; HYPOGLYCEMIA; INCRETIN; TYPE 2 DIABETES MELLITUS;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FASTING; HUMANS; INSULIN; ISLAM; RELIGION AND MEDICINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892453635     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S54585     Document Type: Review

References (40)

1. Pewforum. org [homepage on the Internet]. The future of the global Muslim population: projections for 2010-2030. Washington, DC: Pew Research Center; 2011. Available from: http://www.pewforum.org. Accessed August 28, 2013.
2. Idf. org [homepage on the Internet]. IDF Diabetes Atlas, 5th ed. Brussels, Belgium: International Diabetes Federation; 2011. Available from: http://www.idf.org/diabetesatlas. Accessed August 28, 2013.
3. Salti I, Benard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27(10):2306-2311.
4. Al-Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care. 2010;33(8):1895-1902.
5. Fatima J, Karoli R, Chandra A, Naqvi N. Ramadan fasting in patients with type 2 diabetes mellitus: experience from a teaching hospital. Indian J Endocrinol Metab. 2012;16(2):323-324.
6. Almaatouq MA. Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan. Diabetes Metab Syndr Obes. 2012;5:109-119.
7. Rashed AH. The fast of Ramadan. BMJ. 1992;304(6826):521-522.
8. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med. 2008;25(3):245-254.
9. Ahmad J, Pathan MF, Jaleel MA, et al. Diabetic emergencies including hypoglycemia during Ramadan. Indian J Endocrinol Metab. 2012;16(4):512-515.
10. Loke SC, Rahim KF, Kanesvaran R, Wong TW. A prospective cohort study on the effect of various risk factors on hypoglycaemia in diabetics who fast during Ramadan. Med J Malaysia. 2010;65(1):3-6.
11. Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013;9: 155-163.
12. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34(8):535-542.
13. Tayek J. SUR receptor activity vs incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab. 2008;10(11):1128-1129.
14. Aravind SR, Al Tayeb K, Ismail SB, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011;27(6):1237-1242.
15. Davidson MB. Recommendations for management of diabetes during Ramadan. Diabetes Care. 2006;29(3):745.
16. Elhadd TA, Al-Amoudi AA. Recommendations for management of diabetes during Ramadan. Diabetes Care. 2006;29(3):744-745.
17. Hui E, Devendra D. Diabetes and fasting during Ramadan. Diabetes Metab Res Rev. 2010;26(8):606-610.
18. Aziz KM. Effect of fasting ramadan in diabetes control status-application of extensive diabetes education, serum creatinine with HbA1c statistical ANOVA and regression models to prevent hypoglycemia. Recent Pat Endocr Metab Immune Drug Discov. 2013;7(3): 233-251.
19. Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13(9):775-783.
20. Dejager S, Schweizer A. Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Ther. 2011;2(2):51-66.
21. Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011;65(1):1132-1140.
22. Aravind SR, Ismail SB, Balamurugan R, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012;28(8):1289-1296.
23. Devendra D, Gohel B, Bravis V, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract. 2009;63(10):1446-1450.
24. Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011;27(7):1367-1374.
25. Hanif W, Malik W, Hassanein M, et al. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan. Curr Med Res Opin. 2013;29(7):807-811.
26. Shete AVV, Indian Ramadan study group. Real life experience of usage of vildagliptin versus sulfonylurea therapy in fasting patients with type 2 diabetes during Ramadan: an Indian experience. Diabetologia. 2011; 54 Suppl 1:S342-S343.
27. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res. 2009;41(12):905-909.
28. Halimi S, Levy M, Huet D, Quere S, Dejager S. Experience with vildagliptin in type 2 diabetic patients fasting during ramadan in France: insights from the VERDI study. Diabetes Ther. Epub August 31, 2013.
29. Al-Arouj M, Hassoun AA, Medlej R, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract. 2013;67(10): 957-963.
30. Israelian Z, Szoke E, Woerle J, et al. Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus. Metabolism. 2006;55(5):593-598.
31. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(4):1236-1243.
32. Farngren J, Persson M, Schweizer A, Foley JE, Ahren B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012;97(10):3799-3806.
33. Ahrén B, Farngren J, Persson M, Schweizer A, Foley J. Improved glucagon dynamics during hypoglycemia and food-rechallenge by DPP-4 inhibition by vildagliptin in insulin-treated patients with type 2 diabetes. Diabetologia. 2013;56 Suppl 1:S51.
34. Christensen M, Vedtofte L, Holst JJ, Vilsboll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60(12):3103-3109.
35. Davis JA, Singh S, Sethi S, et al. Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals. Indian J Pharmacol. 2010;42(4):229-233.
36. Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 1999;84(9): 3140-3145.
37. Peacey SR, Rostami-Hodjegan A, George E, Tucker GT, Heller SR. The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans. J Clin Endocrinol Metab. 1997;82(5):1458-1461.
38. Ahrén B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2010;33(4):730-732.
39. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4): 616-631.
40. Novartis Pharmaceuticals. Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan (STEADFAST). Available from: http://clinicaltrials.gov/show/NCT01758380. NLM identifier: NCT01758380. Accessed November 25, 2013.